CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences.
Jefferies Global Healthcare Conference
Date: Thursday, June 6, 2024
Time: 9:30 a.m. ET
Goldman Sachs 45 th Annual Global Healthcare Conferenc e
Date: Monday, June 10, 2024
Time: 10:40 a.m. ET
Live webcasts of the fireside chats will be available on the Investors section of the Company's website at www.omegatherapeutics.com . Archived replays will be available on the same website for approximately 90 days.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.
For more information, visit omegatherapeutics.com , or follow us on X and LinkedIn .
Contact:Eva Stroynowski617.949.4370estroynowski@omegatx.com